Libtayo® (cemiplimab-rwlc) – New drug approval
September 28, 2018 - The FDA announced the approval of Regeneron and Sanofi’s Libtayo (cemiplimab-rwlc), for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Top